Bone marrow aspiration for disseminated tumor cell detection: A must-have test or is the jury still out?

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1531-1533

  Scher, Howard I ^a   Pantel, Klaus ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BLOOD EXAMINATION; BONE MARROW BIOPSY; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CLINICAL PRACTICE; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; HUMAN; IMMUNOCYTOCHEMISTRY; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MICRODISSECTION; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TUMOR CELL; TUMOR LOCALIZATION;

BIOPSY, NEEDLE; BONE MARROW NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 63749110140     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.2092     Document Type: Editorial

References (24)

1. Weckermann D, Polzer B, Ragg T, et al: Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 27:1549-1556, 2009
2. Cristofanilli M, Mendelsohn J: Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy? Proc Natl Acad SciUSA 103:1707317074, 2006
3. Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793-802, 2005
4. Wiedswang G, Borgen E, Karesen R, et al: Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10:5342-5348, 2004
5. Janni W, Rack B, Schindlbeck C, et al: The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increasedrisk for recurrence. Cancer 103:884-891, 2005
6. Naume B, Fehm T, Wiedswang G, et al: Persistence of isolated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse - a European pooled analysis. San Antonio Breast Cancer Symposium 2008
7. US Food and Drug Administration: Memorandum of understanding between Food and Drug Administration (FDA) and the National Cancer Institute (NCI) and Centers for Medicare and Medicaid services. http://www.fda.gov/oc/mous/domestic/ FDA-NCI-CMS.html
8. Scher HI, Heller G: Clinical states in prostate cancer: Towards a dynamic model of disease progression. Urology 55:323-327, 2000
9. Pantel K, Brakenhoff RH, Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329-340, 2008
10. Fehm T, Braun S, Muller V, et al: A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107:885-892, 2006
11. DISMAL Project: http://www.dismal-project.eu/
12. Shariat SF, Walz J, Roehrborn CG, et al: External validation of a biomarker- based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol 26:1526-1531, 2008
13. Kollermann J, Weikert S, Schostak M, et al: Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 26:4928-4933, 2008
14. Veridex: 501(k) Summary. http://www.fda.gov/cdrh/pdf7/K073338.pdf
15. de Bono JS, Scher HI, Montgomery B, et al: Circulating tumor cells predict overall survival following treatment in metastatic prostate cancer. Clinical Cancer Res 14:6302-6309, 2008
16. Muller V, Stahmann N, Riethdorf S, et al: Circulating tumor cells in breast cancer: Correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11:3678-3685, 2005
17. Pierga JY, Bonneton C, Vincent-Salomon A, et al: Clinical significance of immu- nocytochemical detection of tumor cellsusing digital microscopyin peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 10:1392-1400, 2004
18. Pantel K, Schlimok G, Braun S, et al: Differential expression of proliferation- associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419-1424, 1993
19. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 4:448-456, 2004
20. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834-846, 2007
21. Pantel K, Alix-Panabieres C, Riethdorf S: Cancer micrometastases. Nature Clin Pract Oncol (in press)
22. Pantel K, Schlimok G, Angstwurn M, et al: Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3:165-173, 1994
23. Holcomb IN, Grove DI, Kinnunen M, et al: Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 68:5599-5608, 2008
24. Schmidt H, DeAngelis G, Eltze E, et al: Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res 66:8959-8965, 2006